Initiation of Global Phase 3 Trial of Alagille Syndrome Treatment
source: pixabay.com

Initiation of Global Phase 3 Trial of Alagille Syndrome Treatment

Albireo has recently initiated their Phase 3 ASSERT trial, according to GlobeNewswire. This study will evaluate odevixibat as a treatment for Alagille syndrome. This therapy fits well with Albireo's mission,…

Continue Reading Initiation of Global Phase 3 Trial of Alagille Syndrome Treatment

CymaBay Therapeutics Announces Results of Global Phase 3 ENHANCE Study for Primary Biliary Cholangitis

CymaBay Therapeutics, a biopharmaceutical company based in Newark, CA, develops and provides access to novel therapies with a recent focus on primary biliary cholangitis (PBC). The company is currently developing…

Continue Reading CymaBay Therapeutics Announces Results of Global Phase 3 ENHANCE Study for Primary Biliary Cholangitis
ICYMI: Study of Primary Biliary Cholangitis Treatment Shows Positive Results
source: pixabay.com

ICYMI: Study of Primary Biliary Cholangitis Treatment Shows Positive Results

CymaBay Therapeutics has recently released the results from ENHANCE, a study of seladelpar as a treatment for primary biliary cholangitis (PBC). These results were positive, proving that this medication has…

Continue Reading ICYMI: Study of Primary Biliary Cholangitis Treatment Shows Positive Results
The Results from a Primary Biliary Cholangitis Trial Look Promising
source: pixabay.com

The Results from a Primary Biliary Cholangitis Trial Look Promising

According to a story from GlobeNewswire, the biopharmaceutical company CymaBay Therapeutics, Inc. recently announced encouraging topline findings from a phase 3 clinical trial. This study was testing seladelpar as a…

Continue Reading The Results from a Primary Biliary Cholangitis Trial Look Promising
Study Finds That Denosumab can Boost Bone Density in Primary Biliary Cholangitis and Autoimmune Hepatitis
Free-Photos / Pixabay

Study Finds That Denosumab can Boost Bone Density in Primary Biliary Cholangitis and Autoimmune Hepatitis

According to a story from Healio, a recent study has illustrated that the drug denosumab can improve the bone density of patients with primary biliary cholangitis (PBC) and autoimmune hepatitis…

Continue Reading Study Finds That Denosumab can Boost Bone Density in Primary Biliary Cholangitis and Autoimmune Hepatitis
Experimental Treatment for Primary Biliary Cholangitis Earns Orphan Drug Status in the US and EU
Aymanejed / Pixabay

Experimental Treatment for Primary Biliary Cholangitis Earns Orphan Drug Status in the US and EU

According to a story from Markets Insider, the biopharmaceutical company GENFIT recently announced that both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have awarded…

Continue Reading Experimental Treatment for Primary Biliary Cholangitis Earns Orphan Drug Status in the US and EU

FDA Clears Phase 2 Trial for Possible Idiopathic Pulmonary Fibrosis Drug

According to a story from BioPortfolio, the biopharmaceutical company Genkyotex has recently announced that the US Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application.…

Continue Reading FDA Clears Phase 2 Trial for Possible Idiopathic Pulmonary Fibrosis Drug
Positive Results in Mouse Model for Experimental Drug Treating Liver Scarring Associated With Nonalcoholic Steatohepatitis (NASH)
Alexas_Fotos / Pixabay

Positive Results in Mouse Model for Experimental Drug Treating Liver Scarring Associated With Nonalcoholic Steatohepatitis (NASH)

According to a story from globenewswire.com, the biopharmaceutical company ContraVir Pharmaceuticals, Inc. has recently announced that its experimental drug CRV431 was able to successfully decrease scarring of the liver in…

Continue Reading Positive Results in Mouse Model for Experimental Drug Treating Liver Scarring Associated With Nonalcoholic Steatohepatitis (NASH)

Mouse Model Continues to Show Efficacy of GKT831 for Treating Cholestatic Fibrosis in Primary Biliary Cholangitis

Preclinical data supporting the efficacy of GKT831 as a potential therapy for cholestatic fibrosis has just been published in the Journal of Hepatology. GKT831 GKT831 is both a NOX1 enzyme and…

Continue Reading Mouse Model Continues to Show Efficacy of GKT831 for Treating Cholestatic Fibrosis in Primary Biliary Cholangitis

New Potential Primary Biliary Cholangitis Treatment Granted Breakthrough Therapy Designation

Researchers at GENFIT are excited about promising results from studies investigating a new potential therapy for PBC and NASH, two rare liver diseases. Primary Biliary Cholangitis Primary biliary cholangitis (PBC)…

Continue Reading New Potential Primary Biliary Cholangitis Treatment Granted Breakthrough Therapy Designation

The Struggles of being a Rare Disease Patient in China

The State of Rare Diseases in China The Illness Challenge Foundation (ICF) is an organization devoted to easing the burdens that rare disease patients living in China face. They accomplish this…

Continue Reading The Struggles of being a Rare Disease Patient in China

Making Strides Towards New Treatment Options for Nonalcoholic Steatohepatitis

Nonalcoholic steatohepatitis (NASH), is condition most commonly caused by obesity or type 2 diabetes. It can result in fibrosis, complications in the lung and cardiac system, liver cancer, liver cirrhosis,…

Continue Reading Making Strides Towards New Treatment Options for Nonalcoholic Steatohepatitis
Experimental Treatment for Biliary Atresia Gets Orphan Drug Designation in the EU
Capri23auto / Pixabay

Experimental Treatment for Biliary Atresia Gets Orphan Drug Designation in the EU

According to a story from Market Screener, the drug developer Albireo Pharma, Inc., recently announced that its investigational product candidate A4250 has earned Orphan Drug designation from the European Commission.…

Continue Reading Experimental Treatment for Biliary Atresia Gets Orphan Drug Designation in the EU

A Study of a Potential Drug for Primary Biliary Cholangitis has Exceeded its Patient Enrolment Target

The company Genkyotex has announced that they have finished enrolling participants for a Phase 2 clinical trial of the investigational drug GKT831 in patients who have primary biliary cholangitis. The…

Continue Reading A Study of a Potential Drug for Primary Biliary Cholangitis has Exceeded its Patient Enrolment Target